Search alternatives:
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
36281
-
36282
Table_1_A 24-h restraint with food and water deprivation: a potential method to establish a model of depression in pigs.pdf
Published 2023“…After acute stress, pigs exhibited decreased feed intake and sucrose preference, increased serum COR levels, decreased hippocampal 5-HT levels, and exhibited more fear. …”
-
36283
-
36284
-
36285
Baseline characteristics of the study sample<sup>β</sup>μ.
Published 2024“…The mean time needed to resolve a DRP was shortest in Active Group A (7.3 ±3.5 minutes), followed by Active Group B (9.8 ±4.2 minutes) and the Control Group (9.8 ±5.7 minutes).…”
-
36286
The flow diagram of the study (CONSORT, 2010).
Published 2024“…The mean time needed to resolve a DRP was shortest in Active Group A (7.3 ±3.5 minutes), followed by Active Group B (9.8 ±4.2 minutes) and the Control Group (9.8 ±5.7 minutes).…”
-
36287
Purification and Characterization of the Fe<sup>II</sup>- and α-Ketoglutarate-Dependent Xanthine Hydroxylase from <i>Aspergillus nidulans</i><sup>†</sup>
Published 2007“…The αKG cosubstrate can be substituted with α-ketoadipate (9-fold decrease in <i>k</i><sub>cat</sub> and 5-fold increase in the <i>K</i><sub>m</sub> compared to those of the normal α-keto acid), while the αKG analogue <i>N</i>-oxalylglycine is a competitive inhibitor (<i>K</i><sub>i</sub> = 0.12 μM). …”
-
36288
Vanadium Oxides on Aluminum Oxide Supports. 3. Metastable κ-Al<sub>2</sub>O<sub>3</sub>(001) Compared to α-Al<sub>2</sub>O<sub>3</sub>(0001)
Published 2007“…On the α-Al<sub>2</sub>O<sub>3</sub>(0001) surface, the only stable low-coverage VO<i><sub>x</sub></i> species are dimers with V−O<sup>(2)</sup>−Al interface bonds and a defect formation energy of 2.8 eV. …”
-
36289
Sensitivity of the long-term reduction in microfilarial load in individuals under 20 years of age to the assumed rate of decay of vaccine efficacy.
Published 2015“…<p>The mean duration of vaccine prophylactic (against incoming L3 larvae) and therapeutic (against microfilariae) activity is 1/the rate of decay (i.e. 5, 10, 20 and 50 years). …”
-
36290
-
36291
-
36292
-
36293
Descriptive statistics.
Published 2023“…Results also show that a decrease in under-five mortality is associated with a decline in fertility over the sample period. …”
-
36294
Time courses of evoked VSD response at the stimulation site.
Published 2015“…Typically, a fast initial increase of fluorescence was followed by a fast decrease, then a slow decrease or slow undershoot below the baseline. …”
-
36295
-
36296
-
36297
TK1 protein levels do not reflect p-ERK attenuation following inhibition of <sup>V600E</sup>BRAF inhibition in COLO 205 cells.
Published 2014“…<p>COLO 205 cells were collected 48 hours of PLX 4032 exposure at 10 nM, 100 nM, 500 nM, 1 µM, or 5 µM. (<b>A</b>) Western blot analysis demonstrated target inhibition of p-MEK despite increased p-ERK levels. …”
-
36298
-
36299
Reaction Mechanism Underlying Pd(II)-Catalyzed Oxidative Coupling of Ethylene and Benzene to Form Styrene: Identification of a Cyclic Mono-Pd<sup>II</sup> Bis-Cu<sup>II</sup> Compl...
Published 2022“…The PdCu<sub>2</sub>(μ-OAc)<sub>6</sub> cyclic trimer leads to a CMD barrier of 33.5 kcal/mol, while the [Pd(μ-OAc)<sub>2</sub>]<sub>3</sub> species leads to a larger CMD barrier at >35 kcal/mol. …”
-
36300
Image1_The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases.TIF
Published 2022“…<p>Due to the relatively high recurrence rate and the destructive nature of the tumor, the treatment of giant cell tumor is still a challenge. Denosumab appeared to be a promising candidate as a therapeutic drug. …”